DOSE DELIVERED IN 5 MINUTES
Once the injection preparation and application are complete.
Learn how AbbVie could help you save on SKYRIZI.
Call 1.866.SKYRIZI or click tap to learn more ▸
After 3 Starter Doses
Start SKYRIZI with 3 infusions through a vein in your arm (intravenous infunsion).
Each dose consists of a 600 mg intravenous infusion.
Continue SKYRIZI at home with an under-the-skin (subcutaneous) injection using the prefilled cartridge with the SKYRIZI On-Body Injector (OBI).
Each dose consists of 180 mg/1.2 mL or 360 mg/2.4 mL subcutaneous injection via OBI. Your doctor will decide what maintenance dose is right for you.
Start
at a Healthcare Facility
Start SKYRIZI with 3 infusions through a vein in your arm (intravenous infusion), administered by a healthcare provider.
Each dose consists of a 600 mg intravenous infusion.
Maintain
at Home Every 8 Weeks
Continue SKYRIZI at home, after receiving training from a healthcare professional, with an under-the-skin (subcutaneous) injection using the prefilled cartridge with the SKYRIZI On-Body Injector (OBI).
Each dose consists of 180 mg/1.2 mL or 360 mg/2.4 mL subcutaneous injection via OBI.
Your doctor will decide what maintenance
dose is right for you.
See the SKYRIZI Instructions for Use for the
full set of detailed instructions on the
preparation and administration of SKYRIZI.
The SKYRIZI OBI gives you the convenience to administer your maintenance doses at home. With hands-free dosing, you can do moderate physical activities, such as walking, reaching, and bending during treatment. The OBI also features lights and sounds that notify you when the full dose has been delivered and the OBI can be removed.
DOSE DELIVERED IN 5 MINUTES
Once the injection preparation and application are complete.
DOSE DELIVERED IN 5 MINUTES
Once the injection preparation and application are complete.
PREFILLED CARTRIDGE
No measuring medication.
HIDDEN NEEDLE
Discreet injection so you don’t see the needle.
HIDDEN NEEDLE
Discreet injection so you don’t see the needle.
PREFILLED CARTRIDGE
No measuring medication.
COMPACT SIZE
Fits in the palm of your hand.
COMPACT SIZE
Small enough to fit in the palm of the hand.
Your healthcare provider will show you how to administer your at-home dose. See the SKYRIZI Instructions for Use for the full set of detailed instructions on the preparation and administration of SKYRIZI.
In a survey of the SKYRIZI OBI in patients with moderate to severe Crohn’s disease, patient-reported experience was collected using a Self-Injection Assessment Questionnaire (SIAQ). Patients were given the questionnaire after injection training by a healthcare provider (HCP) and following their first self-injection. 41 out of 44 patients reported the OBI was either “easy” or “very easy” to use.
HOW TO USE SKYRIZI: See the detailed “Instructions for Use” that comes with SKYRIZI for information on how to prepare and inject a dose of SKYRIZI, and how to properly throw away (dispose of) a used SKYRIZI prefilled cartridge with the OBI. Before self-injecting with SKYRIZI prefilled cartridge with OBI, your healthcare provider should show you how to inject SKYRIZI.
After your healthcare professional has shown you how to administer your at-home treatment with the SKYRIZI OBI, watch this video if you ever need a refresher.
SKYRIZI Complete can offer support and answers to dosing, savings, and insurance questions.
Up Next
Consider the benefits and risks of taking SKYRIZI to make an informed treatment choice with your doctor.
Recommended for You
See how SKYRIZI can provide symptom relief, remission, and endoscopic improvement.
SKYRIZI is a prescription medicine used to treat moderate to severe Crohn's disease in adults.
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.
Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"
Liver problems may happen while being treated for Crohn's disease or ulcerative colitis: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.
The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.
The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.
These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use it.
SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.
SKYRIZI is a prescription medicine used to treat adults with:
US-SKZ-240065
Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/PatientAccessSupport to learn more.
Legal Notices. © 2024 AbbVie. All rights reserved. If you have any questions about AbbVie’s SKYRIZI.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.